Recently, NanjingKing-Friend Biochemical Pharmaceutical Co., LTD. (hereinafter referred to as "King-Friend") has received an approval letter from the US Food and Drug Administration (hereinafter referred to as "FDA") for its Cyanocobalamin Injection, allowing it to be marketed and sold.

 Cyanocobalamin Injection is indicated for the treatment of children and adult patients with acquired methemoglobinemia.

As an essential water-soluble vitamin for the human body,  Cyanocobalamin Injection plays a core role in hematopoietic function, nervous system maintenance and methyl metabolism. The approval of King-Friend Cyanocobalamin Injection provides a more reliable vitamin supplementation treatment plan for global clinical practice, helping patients regain their body balance and health vitality.